Next Article in Journal
Development of Provesicular Nanodelivery System of Curcumin as a Safe and Effective Antiviral Agent: Statistical Optimization, In Vitro Characterization, and Antiviral Effectiveness
Previous Article in Journal
Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 23
10.3390/molecules25235667
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives

by
Ming-Shu Wang
†,
Yi Gong
†,
Zhi-Cheng Yu
,
Yan-Guang Tian
,
Lin-Sheng Zhuo
*,
Wei Huang
* and
Neng-Fang She
*
Key Laboratory of Pesticide & Chemical Biology of Ministry of Education, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2020, 25(23), 5667; https://doi.org/10.3390/molecules25235667
Submission received: 3 November 2020 / Revised: 26 November 2020 / Accepted: 27 November 2020 / Published: 1 December 2020
Browse Figures
Versions Notes

Abstract

:
A robust, practical, and scalable approach for the construction of 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives 13 via the addition of Grignard reagents to 4-amino-2-chloronicotinonitrile (15) was developed. Starting with various Grignard reagents, a wide range of 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives 13 were conveniently synthesized in moderate-to-good yields through addition–acidolysis–cyclocondensation. In addition, the robustness and applicability of this synthetic route was proven on a 100 g scale, which would enable convenient sample preparation in the preclinical development of 1,6-naphthyridin-4-one-based MET-targeting antitumor drug candidates.

Graphical Abstract

1. Introduction

Naphthyridine scaffolds represent attractive building blocks widely used in pharmaceuticals [1,2], agrochemicals [3], and fluorescent probes [4,5,6]. Recently, it has been reported that numerous naphthyridine-containing molecules have promising medicinal properties for the prevention and treatment of angiogenic disorders [7], viral infections [8,9], bacterial infections [10,11,12], parasitic infections [13], heart failure [14], Alzheimer’s disease (AD) [15], and cancers [16,17,18,19,20,21,22,23,24]. Therefore, the construction of naphthyridines has received increasing attention recently [25].
There are six naphthyridine isomers (1,5-, 1,6-, 1,7-, 1,8- 2,6-, and 2,7-pyridopyridines) [2]. Nowadays, the synthesis of 1,6-naphthyridine, especially for 1,6-naphthyridin-4-one derivatives, has attracted continuous interest in the pharmaceutical industry for its wide-ranging pharmacological activity [26,27], and it has been used as a multi-kinase inhibitor (I) [28], an anti-HCMV inhibitor (II) [29], an antidiabetic agent (III) [30], and antibacterial [31] and antiviral agents (IV) [1] (Figure 1).
In our previous report, 3-phenyl-1,6-naphthyridin-4-one was developed as a potent privileged skeleton for the discovery of a MET kinase inhibitor [20,21,22,23] from the key building block of 5-chloro-3-phenyl-1,6-naphthyridin-4-one (V). Extensive structure–activity relationship (SAR) studies and biological evaluations resulted in the discovery of two MET-targeting antitumor drug candidates, namely, VIa [20] and VIb [23], which are near the clinical stage (Figure 2). In addition to being used as MET kinase inhibitors, 3-phenyl-1,6-naphthyridin-4-one derivatives have also been reported as α7 nAChR allosteric modulators VII by ANVYL, LLC and its copartner (Figure 2) [32,33]. Thus, we propose that diversity-oriented synthesis (DOS), starting from 5-chloro-3-phenyl-1,6-naphthyridin-4-one (V), would resulted in more new drug lead compounds VIII based on the highly reactive 5-halo group and the functionalizable NH group.
However, the construction of the key 3-phenyl-1,6-naphthyridin-4-one skeleton has proven to be difficult. Currently, the reported procedures for its synthesis can be mainly divided into two types (Scheme 1a,b). The first method involves the preparation of an ethyl-2-(4,6-dichloro-nicotinoyl)-3-(dimethylamino)acrylate intermediate (4), followed by strong base-catalyzed cyclization to generate the desired naphthyridine scaffold 5. Then, the halodecarboxylation of intermediate 5 followed by Suzuki–Miyaura coupling with an arylboronic acid results in a 7-functionalized 1,6-naphthyridin-4-one 7 (Scheme 1a) [34]. Obviously, the synthetic route described above has inherent issues, including: (i) it is a labor-intensive process (five-step sequence); (ii) non-applicability on a large scale (due to the physical limitation of microwave heating, the penetration depth of only a few centimeters, and the limited dimensions of standing wave cavities) [35]; (iii) overfunctionalization of the N-position restricts its application in the drug discovery process for which N-substituents need to be finely regulated (the synthesis of the 1,6-naphthyridin-4-one scaffold, keeping a free NH, using this synthetic route has not been reported and the introduction of N-substituents in the initial step of the synthetic route makes the substituent regulation process very cumbersome) [36]. The second method was reported by ANVYL,LLC in their α7 nAChR allosteric modulators study [33], as well as our team in our MET kinase inhibitor study (Scheme 1b) [22]; knowledge of the mechanism of Conrad–Limpach cyclizations led to the introduction of a thermal cyclization to generate the desired naphthyridine scaffold. However, thermal cyclization is typically carried out in diphenyl ether at 230 °C, and the lost control of chemoselectivity results in the generation of 13a and 14 in almost the same proportions. The high reaction temperature and the lack of chemoselectivity have resulted in the complex synthesis of product compositions and low yields (8.2% for three steps), consequently leading to a labor-intensive enrichment and purification process.
Altogether, the construction of 3-phenyl-1,6-naphthyridin-4-one derivatives is still a challenging subject. With our ongoing research interests in the discovery and development of 1,6-naphthyridin-4-one derivatives as drug candidates, we propose a facile Grignard reagent-based strategy through addition–acidolysis–cyclocondensation to provide diversified 5-chloro-3-substituted-1,6-naphthyridin-4-one derivatives 13 (Scheme 1c).

2. Results and Discussion

First, 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one (13a), which is the key common intermediate of our reported MET-targeting drug candidates, was chosen as a target molecule for the preliminary exploration of new synthetic routes. By retrosynthetic analysis, we reasoned that the cyclocondensation of 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a) and triethyl orthoformate would provide the desired molecule 13a (Scheme 2). Moreover, our way to intermediate (17a) is based on the inclusion of a nitrile substituent at the 3-position of 4-amino-2-chloronicotinonitrile to enable the generation of an α-keto group via Grignard chemistry.
The overall synthetic route of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one (13a) is shown in Scheme 3. The formation of 1-(4-amino-2-chloropyridin-3-yl)-2- (4-fluorophenyl)ethan-1-one (17a) was investigated first using 4-amino-2-chloronicotinonitrile (15) and 4-fluorobenzylmagnesium chloride (16a) (Scheme 4 and Table 1).
We initially subjected the two reactants to reaction at 25 °C for 16 h in two different solvents commonly used in Grignard chemistry, and it is obvious that diethyl ether exhibited a better effect on the reaction to provide product 17a than THF (Table 1, entries 1 and 2). It is also worth noting that the incomplete consumption of 4-amino-2-chloronicotinonitrile (15) was observed. Taking into consideration that lower temperatures can result in incomplete consumption and require longer reaction times, the reaction was warmed to 30 °C. After 12 h of reaction, the consumption of 4-amino-2-chloronicotinonitrile (15) was no longer detected by HPLC dynamic detection, and the desired product 17a was obtained at a 35% yield (Table 1, entry 3). Due to the low boiling point of ether, the temperature could not be increased further. Thus, different inert solvents with higher boiling points were evaluated as latent solvents in view of their versatility demonstrated in the Grignard reaction. Regrettably, lower yields were obtained if methyl tert-butyl ether (MTBE) and isopropyl ether (IPE) were utilized (Table 1, entries 4 and 5), and toluene did not favor the transformation either (Table 1, entry 6). Finally, we optimized the reaction by changing the concentration of the Grignard reagent. As highlighted in Table 1 (entries 7–9), increasing the amount of Grignard reagent to 4.0 eqs afforded total consumption of 4-amino-2-chloronicotinonitrile (15) and resulted in a 74% yield of the desired product (Table 1, entries 7 and 8). However, a further increase did not result in a further increase in yield (Table 1, entry 9), suggesting that 4.0 equiv. is the best amount. In summary, 1.0 equiv. of 4-amino-2-chloronicotinonitrile (15) and 4.0 equiv. of 4-fluorobenzylmagnesium chloride (16a) in ether at 30 °C for 12 h were determined to be the optimum reaction conditions.
With the optimized conditions established, the substrate scope with respect to the Grignard reagent was then evaluated (Scheme 5). It was found that the various Grignard reagents exposed to the optimized conditions smoothly provided the corresponding products 17a–n in moderate to good yields (43–82%). Typically, electron-withdrawing halogens on the benzyl Grignard reagent were well tolerated to provide the corresponding products in moderate-to-good yields (17a, 17c, 17e, and 17f; 58–74%); only the fluorine atom at the C-2 position of the benzyl group had a negative impact on the yield of the final products, which resulted in a relative lower yield of 17b and 17d with yields of 43% and 39%, respectively. Notably, an electron-donating group (EDG) might be slightly better than an electron-withdrawing group (EWG), as exemplified by some typical EDGs, the alkyl-substituted benzyl Grignard reagents 17h–j (75–80%), including the bulky isopropyl group (17k; 71%). Moreover, a naphthyl Grignard reagent and chain-growing alkyl Grignard reagents, such as phenethyl and ethyl Grignard reagents, could also provide good yields (17ln; 67–82%).
With these positive results in hand, the optimal reaction conditions of the cyclocondensation of 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a) were investigated next (Scheme 6 and Table 2). Initially, we investigated cyclocondensation by employing K2CO3 as a base and DMF as a solvent at a temperature of 110 °C. However, only a trace amount of the desired product was formed (Table 2, entry 1). Moreover, the combination of NaH and THF did not work (Table 2, entry 2). This was improved when we switched the inorganic base to an organic base. A 15% yield of the desired product was observed when Et3N was used (Table 2, entry 3), and a consistent improvement in the yield was observed by replacing Et3N with DIPEA or DMAP (Table 2, entries 4 and 5), suggesting that DMAP is the best base. Then, by utilizing DMAP as the base, the solvent effects were also investigated. When triethoxymethane was used as both the reactant and solvent, the yield of the desired product was slightly increased (Table 2, entry 6). Finally, we turned our attention to base loading. By gradually reducing the amount of base, we found that only a catalytic amount of the base was needed (Table 2, entries 6–9).
Next, all of the intermediates synthesized above were subjected to the optimized reaction conditions. To our delight, the reaction demonstrated good compatibility, and a series of 3-substituted 1,6-naphthyridin-4-one derivatives were obtained smoothly with moderate-to-good yields (Scheme 7, 13a–o; 40–82%). Generally, both 3-aryl-1,6-naphthyridin-4-one derivatives (13al; 40–82%) and 3-alkyl-1,6-naphthyridin-4-one derivatives (13m and 13n; 74% and 55%) could be readily constructed, and the substituents on the benzene ring had less influence on the yields, except for an ortho-fluorine (13b and 13d; 46% and 40%). Moreover, through changing the reactant triethyl orthoformate into triethyl orthoacetate, a methyl could be smoothly introduced to the C-2 position of the scaffold (13o, 69%), which is of great benefit to the study of SARs in drug discovery. Taken together, this approach is a general method for building various 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives.
More importantly, the synthesis of compound 13a was performed on a 100 g scale to demonstrate the robustness and applicability of this synthetic route (Scheme 8). By starting from 153.0 g (1.0 mol) of 4-amino-2-chloronicotinonitrile (15), we obtained the desired product at a yield of 53.3% (total yield for two steps). After completing the enrichment of compound 13a, a kilogram- scale protocol for the creation of our 1,6-naphthyridin-4-one-based MET-targeting antitumor drug candidate VI was applied through acid-catalyzed nucleophilic substitution of 5-Cl atoms with high yields (90%) and simple operation (insensitive to moisture and oxygen; filtration to obtain desired pure product). This would enable convenient sample preparation in the preclinical development of this drug candidate.

3. Conclusions

In conclusion, we have developed a robust, practical, and scalable approach for the construction of 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives 13 via the addition of Grignard reagents to 4-amino-2-chloronicotinonitrile (15). Starting with various Grignard reagents through addition–acidolysis–cyclocondensation, a wide range of 5-chloro-3-substituted-1,6-naphthyridin-4-one derivatives 13 were synthesized in moderate-to-good yields. In addition, the robustness and applicability of this synthetic route was proven on a 100 g scale, which would enable convenient sample preparation in the preclinical development of 1,6-naphthyridin-4-one-based drug candidates. Further extensions of these naphthyridine derivatives in drug discovery are currently underway in our laboratories.

4. Materials and Methods

4.1. General Information

Unless otherwise noted, all chemical reagents were commercially available and treated with standard methods. Silica gel column chromatography (CC). silica gel (200–400 Mesh; Qingdao Makall Group Co., Ltd; Qingdao; China). Solvents were dried in a routine way and redistilled. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen or argon atmosphere. Melting points of compounds were measured on a Melt-Temp II apparatus (BUCHI Labortechnik AG, Uster, Switzerland) and are uncorrected. 1H-NMR spectra (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on an Ultrashield Plus AV 400 spectrometer (Bruker BioSpin AG, Fällanden, Switzerland) as dimethyl sulfoxide-d6 (DMSO-d6) solutions using tetramethylsilane (TMS) as an internal standard (δ = 0) unless noted otherwise. 1H-NMR spectra (600 MHz) and 13C-NMR (150 MHz) spectra were recorded on a Varian Mercury-Plus 600 spectrometer (Varian Inc., Palo Alto, CA, USA) as dimethyl sulfoxide-d6 (DMSO-d6) solutions using tetramethylsilane (TMS) as an internal standard (δ = 0) unless noted otherwise, and all the 1H and 13C NMR Spectra are summarized in the Supplementary Materials. MS spectra were obtained on a 6120 quadrupole LC/MS (ESI, Agilent Technologies, Santa Clara, CA, USA). All reactions were monitored using thin-layer chromatography (TLC, Yantai Jiangyou Silica gel Development Co., Ltd.; Yantai; China) on silica gel plates. Yields were of purified compounds and were not optimized.

4.2. General Procedure I for the Synthesis of 2-Substituted 1-(4-amino-2-chloropyridin-3-yl)-ethan-1-ones 17a–n

The appropriate Grignard reagent 16 (6.0 mmol, 4.0 equivs.) in ether (3.3 mL) was added at room temperature to 4-amino-2-chloronicotinonitrile (15, 230.0 mg, 1.5 mmol) in ether (3.0 mL). The reaction mixture was warmed to 30 °C and stirred for 12 h under ether atmosphere. Then the reaction mixture was cooled to 0 °C and 6.0 mL of mixed solvent (HCl/H2O/EtOH = 1:1:2) was added dropwise, the reaction mixture was refluxed for a further 2 h. After the completion of the reaction, the mixture was neutralized with sodium carbonate solution and extracted with EtOAc (3 × 15 mL). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (hexane/EA = 5:1) to yield the corresponding compound 17 in good yield.
1-(4-Amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a) was prepared from 15 and (4-fluorobenzyl)magnesium chloride (16a) by general procedure I as a white solid (294 mg, 74%), M.p. 130–133 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.81 (d, J = 6.0 Hz, 1H), 7.3 3–7.30 (m, 2H), 7.17–7.12 (m, 2H), 6.61 (d, J = 6.0 Hz, 1H), 6.59 (s, 2H), 4.18 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.5, 161.5 (d, JC–F = 241.0 Hz), 153.7, 149.2, 146.7, 132.3(d, JC–F = 8.0 Hz), 130.5(d, JC–F = 3.0 Hz), 118.8, 115.3(d, JC–F = 24.0 Hz), 110.5, 49.1. MS (ESI): 265.05 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(2-fluorophenyl)ethan-1-one (17b) was prepared from 15 and (2-fluorobenzyl)magnesium chloride (16b) by general procedure I as a white solid (171 mg, 43%), M.p. 127–131 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 6.0 Hz, 1H), 7.47–7.25 (m, 2H), 7.24–7.07 (m, 2H), 6.62 (s, 2H), 6.60 (d, J = 6.0 Hz, 1H), 4.26 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 200.2, 162.2 (d, JC–F = 243.0 Hz), 154.1, 149.3, 147.1, 133.1 (d, JC–F = 5.0 Hz), 129.6 (d, JC–F = 8.0 Hz), 124.6 (d, JC–F = 3.0 Hz), 121.7 (d, JC–F = 16.0 Hz), 118.3, 115.5 (d, JC–F = 21.0 Hz), 110.7, 43.8. MS (ESI): 265.05 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(3-fluorophenyl)ethan-1-one (17c) was prepared from 15 and (3-fluorobenzyl)magnesium chloride (16c) by general procedure I as a white solid (246.3 mg, 62%), M.p. 128–132 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.81 (d, J = 6.0 Hz, 1H), 7.43–7.29 (m, 1H), 7.18–7.02 (m, 3H), 6.62 (s, 2H), 6.60 (d, J = 6.0 Hz, 1H), 4.23 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.0, 162.4 (d, JC–F = 241.0 Hz), 153.8, 149.2, 146.7, 137.1 (d, JC–F = 8.0 Hz), 130.4 (d, JC–F = 8.0 Hz), 126.6 (d, JC–F = 2.0 Hz), 118.8, 117.2 (d, JC–F = 21.0 Hz), 114.1 (d, JC–F = 21.0 Hz), 110.6, 49.5. MS (ESI): 265.05 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(2,4-difluorophenyl)ethan-1-one (17d) was prepared from 15 and (2,4-difluorobenzyl)magnesium chloride (16d) by general procedure I as a white solid (165.3 mg, 39%), M.p. 180–183 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.83 (d, J = 6.0 Hz, 1H), 7.50–7.38 (m, 1H), 7.26–7.15 (m, 1H), 7.11–7.01 (m, 1H), 6.62 (s, 2H), 6.60 (d, J = 6.0 Hz, 1H), 4.25 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 200.1, 161.9 (dd, JC–F = 241.0 Hz, 12.0 Hz), 161.2 (dd, JC–F = 241.0 Hz, 12.0 Hz), 154.1, 149.3, 147.1, 134.0 (dd, JC–F = 9.0 Hz, 6.0 Hz), 118.2, 118.1 (dd, JC–F = 15.0 Hz, 3.0 Hz), 111.6 (dd, JC–F = 21.0 Hz, 5.0Hz), 110.7, 103.9 (t, JC–F = 26.0 Hz), 43.2. MS (ESI): 283.16 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(4-chlorophenyl)ethan-1-one (17e) was prepared from 15 and (4-chlorobenzyl)magnesium chloride (16e) by general procedure I as a white solid (273 mg, 65%), M.p.147–150 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 6.0 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 6.62 (s, 2H), 6.60 (d, J = 6.0 Hz, 1H), 4.19 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.2, 153.7, 149.2, 146.7, 133.3, 132.2, 132.0, 128.5, 118.7, 110.5, 49.2. MS (ESI): 282.01 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(4-bromophenyl)ethan-1-one (17f) was prepared from 15 and (4-bromobenzyl)magnesium chloride (16f) by general procedure I as a white solid (283.2 mg, 58%), M.p. 132–133 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 6.0 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 6.62 (s, 2H), 6.60 (d, J = 6.0 Hz, 1H), 4.18 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.1, 153.7, 149.2, 146.7, 133.8, 132.6, 131.4, 120.5, 118.7, 110.5, 49.3. MS (ESI): 326.96 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-phenylethan-1-one (17g) was prepared from 15 and benzyl-magnesium chloride (16g) by general procedure I as a white solid (258.9 mg, 70%), M.p.85–87 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.81 (d, J = 6.0 Hz, 1H), 7.33–7.26 (m, 5H), 6.62–6.59 (m, 3H), 4.20 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.6, 153.8, 149.1, 146.7, 134.3, 130.3, 128.6, 127.2, 118.8, 110.5, 50.0. MS (ESI): 247.06 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(p-tolyl)ethan-1-one (17h) was prepared from 15 and (4-methyl-benzyl)magnesium chloride (16h) by general procedure I as a white solid (312 mg, 80%), M.p. 100–103 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.80 (d, J = 6.0 Hz, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 6.60 (d, J = 6.0 Hz, 3H), 4.13 (s, 2H), 2.28 (s, 3H). 13C-NMR (100 MHz, DMSO-d6) δ 201.7, 153.8, 148.9, 146.6, 136.2, 131.2, 129.2, 118.8, 110.5, 49.7, 21.1. MS (ESI): 261.32 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(m-tolyl)ethan-1-one (17i) was prepared from 15 and (3-methyl-benzyl)magnesium chloride (16i) by general procedure I as a white solid (297 mg, 76%), M.p. 91–95 °C, 1H-NMR (600 MHz, DMSO-d6) δ 7.80 (d, J = 6.0 Hz, 1H), 7.19 (t, J = 7.2 Hz, 1H), 7.12–7.01 (m, 3H), 6.65–6.52 (m, 3H), 4.14 (s, 2H), 2.28 (s, 3H). 13C-NMR (150 MHz, DMSO-d6) δ 201.7,153.8, 149.3, 146.8, 137.7, 134.3, 131.1, 128.6, 127.9, 127.5, 119.0, 110.6, 50.1, 21.5. MS (ESI): 261.08 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(4-ethylphenyl)ethan-1-one (17j) was prepared from 15 and (4-ethylbenzyl)magnesium chloride (16J) by general procedure I as a white solid (309 mg, 75%), M.p. 89–102 °C, 1H-NMR (600 MHz, DMSO-d6) δ 7.80 (d, J = 6.0 Hz, 1H), 7.20–7.11 (m, 4H), 6.60 (d, J = 6.0 Hz, 3H), 4.14 (s, 2H), 2.57 (q, J = 7.2 Hz, 2H), 1.16 (t, J = 7.2 Hz, 3H). 13C-NMR (150 MHz, DMSO-d6) δ 201.8, 153.88, 149.1, 146.7, 142.7, 131.6, 130.3, 128.1, 119.0, 110.6, 49.7, 28.4, 16.2. MS (ESI): 275.09 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(4-isopropylphenyl)ethan-1-one (17k) was prepared from 15 and (4-isopropylbenzyl)magnesium chloride (16k) by general procedure I as a white solid (307.5 mg, 71%), M.p. 71–75 °C, 1H-NMR (600 MHz, DMSO-d6) δ 7.81 (t, J = 5.2 Hz, 1H), 7.22–7.15 (m, 4H), 6.62 (t, J = 4.4 Hz, 3H), 4.14 (s, 1H), 2.85 (p, J = 6.0 Hz, 1H), 1.27–1.14 (m, 6H). 13C-NMR (150 MHz, DMSO-d6) δ 201.8, 153.9, 149.1, 147.3, 146.7, 131.7, 130.4, 126.6, 119.1, 110.6, 49.7, 33.6, 24.5. MS (ESI): 289.11 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-2-(naphthalen-1-yl)ethan-1-one (17l) was prepared from 15 and (naphthalen-1-ylmethyl)magnesium chloride (16l) by general procedure I as a white solid (297.6 mg, 67%), M.p. 78–80 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.87–7.86 (m, 1H), 7.85–7.84 (m, 1H), 7.83–7.81 (m, 2H), 7.53–7.50 (m, 2H), 7.48–7.46 (m, 2H), 6.66 (s, 2H), 6.65 (d, J = 6.0 Hz, 1H), 4.70 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 201.3, 154.2, 149.0, 147.1, 133.7, 132.6, 131.1, 129.1, 128.8, 128.0, 126.5, 126.1, 125.9, 124.8, 118.6, 110.8, 47.7. MS (ESI): 297.07 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)-3-phenylpropan-1-one (17m) was prepared from 15 and phenethyl- magnesium chloride (16m) by general procedure I as a white solid (320.7 mg, 82%), M.p. 81–83 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.80 (d, J = 6.0 Hz, 1H), 7.41–7.08 (m, 5H), 6.61 (d, J = 6.0 Hz, 1H), 6.58 (s, 2H), 3.15 (t, J = 7.6 Hz, 2H), 2.94 (t, J = 7.6 Hz, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 203.2, 153.8, 149.1, 146.8, 141.1, 128.8, 128.7, 126.4, 118.8, 110.5, 45.3, 29.8.MS (ESI): 261.91 [M + H]+.
1-(4-Amino-2-chloropyridin-3-yl)propan-1-one (17n) was prepared from 15 and ethylmagnesium chloride (16n) by general procedure I as a white solid (210 mg, 75%), M.p. 97–100 °C, 1H-NMR (400 MHz, DMSO-d6) δ 7.80 (d, J = 6.0 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.50 (s, 2H), 2.82 (q, J = 7.2 Hz, 2H), 1.09 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, DMSO-d6) δ 204.7, 153.5, 149.0, 146.5, 119.3, 110.4, 37.1, 8.3. MS (ESI): 185.04 [M + H]+.

4.3. General Procedure II for the Synthesis of 3-Substituted 1,6-naphthyridin-4-ones 13a–o

A solution of 2-substituted 1-(4-amino-2-chloropyridin-3-yl)-ethan-1-one 17 (0.5 mmol) and DMAP (0.5 mmol) in triethyl orthoformate (18a, for 13a–n) or triethyl orthoacetate (18b, for 13o) (1.0 mL) was heated to 110 °C and stirred for 24 h, then cooled to room temperature, the resulted solid was filtered and the filter residue was added to a 5 mL round-bottomed flask charged with 2.0 mL isopropanol, refluxed for 2 h and filtered immediately to afford the corresponding compound 13 in good yield.
5-Chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one (13a) was prepared from 17a and triethyl orthoformate (18a) by general procedure II as a light yellow solid (98 mg, 72%), M.p. 296–299 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.3 (s, 1H), 8.31 (d, J = 5.6 Hz, 1H), 8.15 (s, 1H), 7.69–7.65 (m, 2H), 7.45 (d, J = 5.6 Hz, 1H), 7.25–7.20 (m, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 173.8, 161.8 (d, JC–F = 243.0 Hz), 150.6, 148.2, 147.7, 138.2, 131.8 (d, JC–F = 3.0 Hz), 131.1 (d, JC–F = 7.0 Hz), 124.5, 118.0, 115.1 (d, JC–F = 21.0 Hz), 113.1. MS (ESI): 275.21 [M + H]+.
5-Chloro-3-(2-fluorophenyl)-1,6-naphthyridin-4(1H)-one (13b) was prepared from 17b and triethyl orthoformate (18a) by general procedure II as a light yellow solid (63 mg, 46%), M.p. 264–268 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.38 (s, 1H), 8.33 (d, J = 6.0 Hz, 1H), 8.11 (s, 1H), 7.54–7.34 (m, 3H), 7.32–7.14 (m, 2H). 13C-NMR (150 MHz, DMSO-d6) δ 173.2, 160.7 (d, JC–F = 244.5 Hz), 150.4, 148.4, 147.9, 139.2, 132.6, 129.9 (d, JC–F = 7.5 Hz), 124.4, 123.3 (d, JC–F = 13.5 Hz), 121.3, 117.6, 115.7 (d, JC–F = 22.5 Hz), 113.1. MS (ESI): 275.23 [M + H]+.
5-Chloro-3-(3-fluorophenyl)-1,6-naphthyridin-4(1H)-one (13c) was prepared from 17c and triethyl orthoformate (18a) by general procedure II as a light yellow solid (87.9 mg, 64%), M.p. 273–275 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.33 (d, J = 6.0 Hz, 1H), 8.25 (s, 1H), 7.59–7.38 (m, 4H), 7.20–7.10 (m, 1H). 13C-NMR (150 MHz, DMSO-d6) δ 173.7, 162.3 (d, JC–F = 244.5 Hz), 150.7, 148.4, 147.7 (d, JC–F = 4.5 Hz), 138.9, 137.9, 130.2, 125.0, 123.9 (d, JC–F = 4.5 Hz), 118.1 (d, JC–F = 4.5 Hz), 115.8 (d, JC–F = 22.5 Hz), 114.2 (d, JC–F = 13.5 Hz), 113.15, MS (ESI): 275.03 [M + H]+.
5-Chloro-3-(2,4-difluorophenyl)-1,6-naphthyridin-4(1H)-one (13d) was prepared from 17d and triethyl orthoformate (18a) by general procedure II as a light yellow solid (58.5 mg, 40%), M.p. 238–241 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.58 (s, 1H), 8.89 (s, 1H), 7.93 (d, J = 6.0 Hz, 1H), 7.68–7.62 (m, 1H), 7.46 (td, J1 = 9.6 Hz, J2 = 2.4 Hz, 1H), 7.28 (td, J1 = 8.4 Hz, J2 = 2.4 Hz, 1H), 7.05 (d, J = 6.0 Hz, 1H). 13C-NMR (100 MHz, DMSO-d6) δ 171.6, 165.9 (dd, JC–F = 298.0 Hz, 12.0 Hz), 163.0 (dd, JC–F = 298.0 Hz, 12.0 Hz), 160.6, 149.3, 148.2, 139.0, 133.8 (dd, JC–F = 10.0 Hz, 4.0 Hz), 116.5, 116.1 (dd, JC–F = 15.0 Hz, 4.0 Hz), 112.4, (dd, JC–F = 21.0 Hz, 4.0 Hz), 109.1, 104.9 (t, JC–F = 21.0 Hz), 101.7. MS (ESI): 293.42 [M + H]+.
5-Chloro-3-(4-chlorophenyl)-1,6-naphthyridin-4(1H)-one (13e) was prepared from 17e and triethyl orthoformate (18a) by general procedure II as a light yellow solid (88.5 mg, 61%), M.p. 196–200 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.60 (s, 1H), 8.32 (d, J = 6.0 Hz, 1H), 8.19 (s, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 6.0 Hz, 1H), 7.45 (d, J = 8.4 Hz, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 173.7, 150.6, 148.2, 147.6, 138.4, 134.3, 132.0, 130.8, 128.3, 124.0, 118.0, 113.1. MS (ESI): 292.11 [M + H]+.
3-(4-Bromophenyl)-5-chloro-1,6-naphthyridin-4(1H)-one (13f) was prepared from 17f and triethyl ortho- formate (18a) by general procedure II as a light yellow solid (85.6 mg, 51%), M.p. 239–241 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.32 (d, J = 6.0 Hz, 1H), 8.18 (s, 1H), 7.64–7.58 (m, 4H), 7.45 (d, J = 6.0 Hz, 1H). 13C-NMR (100 M, DMSO-d6) δ 173.6, 150.6, 148.2, 147.6, 138.3, 134.7, 131.2, 131.1, 124.1, 120.6, 118.0, 113.0. MS (ESI): 336.95 [M + H]+.
5-Chloro-3-phenyl-1,6-naphthyridin-4(1H)-one (13g) was prepared from 17g and triethyl orthoformate (18a) by general procedure II as a light yellow solid (89.8 mg, 69%), M.p. 198–200 °C, 1H-NMR (400 MHz, DMSO-d6) δ12.22 (s, 1H), 8.21 (d, J = 6.0 Hz, 1H), 8.03 (d, J = 5.6 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.52 (s, 1H), 7.38–7.18 (m, 4H). 13C-NMR (100 MHz, DMSO-d6) δ 173.9, 150.7, 148.1, 147.7, 138.1, 135.5, 129.2, 128.3, 127.5, 125.6, 118.0, 113.0. MS (ESI): 292.11 [M + H]+.
5-Chloro-3-(p-tolyl)-1,6-naphthyridin-4(1H)-one (13h) was prepared from 17h and triethyl ortho- formate (18a) by general procedure II as a light yellow solid (110.9 mg, 82%), M.p. 222–225 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.28 (s, 1H), 8.30 (d, J = 6.0 Hz, 1H), 8.09 (s, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 6.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 2H), 2.33 (s, 3H). 13C-NMR (100 MHz, DMSO-d6) δ173.9, 150.6, 148.0, 147.5, 137.7, 136.6, 132.5, 128.9, 128.8, 125.4, 117.9, 113.0, 21.2. MS (ESI): 271.85[M + H]+.
5-Chloro-3-(m-tolyl)-1,6-naphthyridin-4(1H)-one (13i) was prepared from 17i and triethyl orthoformate (18a) by general procedure II as a light yellow solid (83.9 mg, 62%), M.p. 257–261 °C, 1H-NMR (600 MHz, DMSO-d6) δ 12.32 (s, 1H), 8.31 (d, J = 6.0 Hz, 1H), 8.12 (s, 1H), 7.46 –7.44 (m, 2H), 7.40 (d, J = 6.0 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 2.35 (s, 3H). 13C-NMR (150 MHz, DMSO-d6) δ 173.9, 150.7, 148.2, 147.7, 138.1, 137.3, 135.5, 129.8, 128.3, 128.2, 126.3, 125.7, 118.0, 113.1, 21.7. MS (ESI): 271.85[M + H]+.
5-Chloro-3-(4-ethylphenyl)-1,6-naphthyridin-4(1H)-one (13j) was prepared from 17J and triethyl ortho- formate (18a) by general procedure II as a light yellow solid (85.4 mg, 60%), M.p. 270–273 °C, 1H-NMR (600 MHz, DMSO-d6) δ 12.30 (s, 1H), 8.30 (d, J = 6.0 Hz, 1H), 8.11 (s, 1H), 7.57–7.49 (m, 2H), 7.45 (d, J = 6.0 Hz, 1H), 7.23 (d, J = 7.2 Hz, 2H), 2.62 (q, J = 7.2 Hz, 2H), 1.20 (t, J = 7.2 Hz, 3H). 13C-NMR (150 MHz, DMSO-d6) δ 174.0, 150.7, 148.2, 147.7, 143.2, 137.9, 132.9, 129.2, 127.9, 125.6, 118.0, 113.1, 28.5, 16.3. MS (ESI): 285.65[M + H]+.
5-Chloro-3-(4-isopropylphenyl)-1,6-naphthyridin-4(1H)-one (13k) was prepared from 17k and triethyl orthoformate (18a) by general procedure II as a light yellow solid (91.1 mg, 61%), M.p. 303–304 °C, 1H-NMR (600 MHz, DMSO-d6) 12.39 (s, 1H), 8.42 (d, J = 6.0 Hz, 1H), 8.24 (s, 1H), 7.60 (d, J = 6.0 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 2.99–2.86 (m, 1H), 1.23 (d, J = 7.2 Hz, 6H). 13C-NMR (150 MHz, DMSO-d6) δ 174.0, 150.7, 148.1, 147.8, 147.7, 137.9, 133.1, 129.2, 126.3, 125.7, 118.0, 113.1, 33.8, 24.5. MS (ESI): 299.63[M + H]+.
5-Chloro-3-(naphthalen-1-yl)-1,6-naphthyridin-4(1H)-one (13l) was prepared from 17l and triethyl orthoformate (18a) by general procedure II as a light yellow solid (96.6 mg, 63%), M.p. 281–283 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.12–8.07 (m, 1H), 8.01–7.91 (m, 2H), 7.71–7.63 (m, 1H), 7.62–7.49 (m, 3H), 7.49–7.37 (m, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 174.3, 150.6, 148.3, 148.2, 139.2, 134.2, 133.6, 132.5, 128.5, 128.4, 128.3, 126.6, 126.3, 126.2, 125.9, 117.8, 113.2. MS (ESI): 307.91[M + H]+.
3-Benzyl-5-chloro-1,6-naphthyridin-4(1H)-one (13m) was prepared from 17m and triethyl orthoformate (18a) by general procedure II as a light yellow solid (100 mg, 74%), M.p. 212–215 °C, 1H-NMR (400 MHz, DMSO-d6) δ 12.00 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 7.89 (s, 1H), 7.39 (d, J = 6.0 Hz, 1H), 7.34–7.21 (m, 4H), 7.21–7.09 (m, 1H), 3.73 (s, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 174.7, 150.3, 147.8, 140.9, 137.3, 129.0, 128.6, 126.3, 126.2, 116.9, 113.4, 33.5. MS (ESI): 271.77 [M + H]+.
5-Chloro-3-methyl-1,6-naphthyridin-4(1H)-one (13n) was prepared from 17n and triethyl orthoformate (18a) by general procedure II as a light yellow solid (53.3 mg, 55%), M.p. 181–185 °C, 1H-NMR (400 MHz, DMSO-d6) δ 11.94 (s, 1H), 8.23 (d, J = 6.0 Hz, 1H), 7.89 (s, 1H), 7.36 (d, J = 6.0 Hz, 1H), 1.93 (s, 3H). 13C-NMR (100 MHz, DMSO-d6) δ 175.6, 150.2, 147.8, 147.5, 136.4, 122.7, 116.3, 112.9, 14.1. MS (ESI): 285.69 [M + H]+.
5-Chloro-3-(4-fluorophenyl)-2-methyl-1,6-naphthyridin-4(1H)-one (13o) was prepared from 17o and triethyl orthoacetate (18b) by general procedure II as a light yellow solid (99.4 mg, 69%), M.p. 309–311 °C, 1H-NMR (600 MHz, DMSO-d6) δ 12.02 (s, 1H), 8.28 (d, J = 6.0 Hz, 1H), 7.40 (d, J = 6.0 Hz, 1H), 7.30–6.98 (m, 4H), 2.16(s, 3H). 13C-NMR (150 MHz, DMSO-d6) δ 173.9, 161.8 (d, JC–F = 241.0 Hz), 150.5, 148.3, 147.6, 147.1, 133.2 (d, JC–F = 7.5 Hz), 131.8 (d, JC–F = 1.5 Hz), 124.9, 116.7, 115.3 (d, JC–F = 21.0 Hz), 112.6, 19.1. MS (ESI): 289.51 [M + H]+.

4.4. Scale-Up Experiment

4.4.1. Mass Preparation of 1-(4-Amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a)

To a 5 L four-neck flask 4-amino-2-chloronicotinonitrile 15 (125.0 g, 0.81 mol) and ether (1500 mL) were added, followed by (4-fluorobenzyl)magnesium chloride in ether (16a) (1.8 M, 3.24 mol, 1800 mL, 4.0 equivs.) at room temperature. The mixture was warmed to 30 °C and stirred for 12 h under ether atmosphere. Then the reaction was cooled in an ice-water bath with the reaction flask equipped with a distillation unit, and 3000 mL of mixed solvent (HCl/H2O/EtOH = 1:1:2) was added dropwise, the volatilized ether was recovered with a distillation unit, and the reaction mixture was refluxed for a further 2 h. After the completion of the reaction, ethanol was removed under vacuum, and the residue was stirred for 12 h and filtered to afford 199 g of crude hydrochloride of 17a as a yellow solid. Next, the yellow solid was added to a 2.0 L flask charged with ethanol (720 mL) and warmed up to reflux followed by addition of trimethylamine (0.66 mol, 66.86 g) dropwise. The resulted mixture was refluxed for further 1 h, then cooled to room temperature and stirred overnight. Finally, filtered and the filter cake was washed with 50% ethanol in water to afford 17a as a light yellow solid, (160 g, 75%).

4.4.2. Mass Preparation of 5-Chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one (13a)

To a 2.0 L of four-neck flask equipped with a distillation unit was added 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a, 0.604 mol, 160.0 g) and triethyl orthoformate (18a, 1600 mL), the reaction mixture was warmed up to 100 °C and stirred for 1.5 h, then DMAP (0.1 eq, 0.6 mol, 7.3 g) was added and the stirring was continued for 24 h at 100 °C with the produced ethanol collected by distillation unit. After the completion of the reaction, the mixture was cooled to room temperature and filtered, the filter cake was added to a 2.0 L of four-neck flask charged with 1500 mL isopropanol, refluxed for 5 h and filtered immediately to afford 13a as light yellow solid (123.5 g, 74).

Supplementary Materials

The supplementary materials are available online.

Author Contributions

W.H. and N.-F.S. conceived and designed the experiments; M.W., Y.G., Y.-G.T. and L.-S.Z. performed synthesis; M.-S.W. and L.-S.Z. analyzed the data; M.-S.W., Z.-C.Y. and W.H. wrote the paper. W.H. was responsible for the correspondence of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Key Research and Development Program of China (No. 2017YFA0505200), the Key Research and Development Program of Hubei Province, China (2020BCB042), the Science and Technology Program of Wuhan (No. 2019020701011460). Dedicated to the 100th anniversary of Chemistry at Nankai University.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Tabarrini, O.; Massari, S.; Sancineto, L.; Daelemans, D.; Sabatini, S.; Manfroni, G.; Cecchetti, V.; Pannecouque, C. Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6-Naphthyridone Derivative with Potent and Selective Anti-HIV Activity. ChemMedChem 2011, 6, 1249–1257. [Google Scholar] [CrossRef] [PubMed]
  2. Madaan, A.; Verma, R.; Kumar, V.; Singh, A.T.; Jain, S.K.; Jaggi, M. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. Arch. Pharm. 2015, 348, 837–860. [Google Scholar] [CrossRef] [PubMed]
  3. Martínez-Teipel, B.; Teixidó, J.; Pascual, R.; Mora, M.; Pujolà, J.; Fujimoto, T.; Borrell, J.I.; Michelotti, E.L. 2-Methoxy-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitriles: Versatile Starting Materials for the Synthesis of Libraries with Diverse Heterocyclic Scaffolds. J. Comb. Chem. 2005, 7, 436–448. [Google Scholar] [CrossRef] [PubMed]
  4. Zhang, Y.; Sun, R.; Kang, X.; Wang, D.-H.; Chen, Y. A water-soluble 1,8-naphthyridine-based imidazolium molecular gripper for fluorescence sensing and discriminating of GMP. Dye. Pigment. 2020, 174, 108103. [Google Scholar] [CrossRef]
  5. Ren, R.; Xu, H.-C.; Dong, H.; Peng, H.-T.; Wu, P.-P.; Qiu, Y.; Yang, S.-G.; Sun, Q.; She, N.-F. Ultrafast 2,7-Naphthyridine-Based fluorescent probe for detection of thiophenol with a remarkable Stokes shift and its application In vitro and in vivo. Talanta 2019, 205, 120067. [Google Scholar] [CrossRef]
  6. Sun, Q.; Ren, R.; Wu, P.-P.; Zhuo, L.-S.; Dong, H.; Peng, H.-T.; Cao, Y.-F.; Luo, X.-G.; She, N.-F. A 2, 7-naphthyridine-based fluorescent turn-on probe for detection of biothiols in vitro and in vivo. Dye. Pigment. 2020, 182, 108702. [Google Scholar] [CrossRef]
  7. Mu, X.-Y.; Xu, J.; Zhou, Y.-J.; Li, Y.-L.; Liu, Y.; Wang, X.-S. Convenient synthesis of naphtho[1,6] naphthyridine derivatives under catalyst-free conditions. Res. Chem. Intermed. 2013, 41, 1703–1714. [Google Scholar] [CrossRef]
  8. Singh, I.P.; Kumar, S.; Gupta, S. Naphthyridines with Antiviral Activity-A Review. Med. Chem. 2017, 13, 430–438. [Google Scholar] [CrossRef]
  9. Peese, K.M.; Allard, C.W.; Connolly, T.; Johnson, B.L.; Li, C.; Patel, M.; Sorensen, M.E.; Walker, M.A.; Meanwell, N.A.; McAuliffe, B.; et al. 5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. J. Med. Chem. 2019, 62, 1348–1361. [Google Scholar] [CrossRef]
  10. De Morais Oliveira-Tintino, C.D.; Tintino, S.R.; Muniz, D.F.; dos Santos Barbosa, C.R.; Pereira, R.L.S.; Begnini, I.M.; Rebelo, R.A.; da Silva, L.E.; Mireski, S.L.; Nasato, M.C. Do 1,8-naphthyridine sulfonamides possess an inhibitory action against TetK and MrsA efflux pumps in multiresistant Staphylococcus aureus strains? Microb. Pathog. 2020, 147, 104268. [Google Scholar] [CrossRef]
  11. Yoo, B.K.; Triller, D.M.; Yong, C.-S.; Lodise, T.P. Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. Ann. Pharmacother. 2004, 38, 1226–1235. [Google Scholar] [CrossRef] [PubMed]
  12. Hong, C.Y.; Kim, Y.K.; Chang, J.H.; Kim, S.H.; Choi, H.; Nam, D.H.; Kim, Y.Z.; Kwak, J.H. Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8] naphthyridine-3-carboxylic Acid (LB20304). J. Med. Chem. 1997, 40, 3584–3593. [Google Scholar]
  13. Thomas, M.; De Rycker, M.; Wall, R.J.; Spinks, D.; Epemolu, O.; Manthri, S.; Norval, S.; Osuna-Cabello, M.; Patterson, S.; Riley, J. Identification and optimisation of a series of 8-hydroxy naphthyridines with potent in vitro antileishmanial activity: Initial SAR and assessment of in vivo activity. J. Med. Chem. 2020, 63, 9523–9539. [Google Scholar] [CrossRef]
  14. Meredith, E.L.; Ardayfio, O.; Beattie, K.; Dobler, M.R.; Enyedy, I.; Gaul, C.; Hosagrahara, V.; Jewell, C.; Koch, K.; Lee, W.; et al. Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors. J. Med. Chem. 2010, 53, 5400–5421. [Google Scholar] [CrossRef] [PubMed]
  15. Fiorito, J.; Vendome, J.; Saeed, F.; Staniszewski, A.; Zhang, H.; Yan, S.; Deng, S.-X.; Arancio, O.; Landry, D.W. Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer’s Disease. J. Med. Chem. 2017, 60, 8858–8875. [Google Scholar] [CrossRef] [PubMed]
  16. Srivastava, S.K.; Jha, A.; Agarwal, S.K.; Mukherjee, R.; Burman, A.C. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anti Cancer Agents Med. Chem. 2007, 7, 685–709. [Google Scholar] [CrossRef]
  17. Zhuo, L.-S.; Xu, H.; Wang, M.-S.; Zhao, X.-E.; Ming, Z.-H.; Zhu, X.-L.; Huang, W.; Yang, G. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development. Eur. J. Med. Chem. 2019, 178, 705–714. [Google Scholar] [CrossRef]
  18. Wang, M.-S.; Xu, H.; Gong, Y.; Qu, R.-Y.; Zhuo, L.-S.; Huang, W. Efficient Arylation of 2,7-Naphthyridin-1(2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor. ACS Comb. Sci. 2020, 22, 9, 457–467. [Google Scholar] [CrossRef]
  19. Sun, H.; Zhuo, L.; Dong, H.; Huang, W.; She, N.-F. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors. Molecules 2019, 24, 4461. [Google Scholar] [CrossRef] [Green Version]
  20. Chen, T.; Zhuo, L.-S.; Liu, P.-F.; Fang, W.-R.; Li, Y.; Huang, W. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate. Eur. J. Med. Chem. 2020, 192, 112174. [Google Scholar] [CrossRef]
  21. Xu, H.; Wang, M.; Wu, F.; Zhuo, L.; Huang, W.; She, N.-F. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorganic Med. Chem. 2020, 28, 115555. [Google Scholar] [CrossRef] [PubMed]
  22. Wang, M.-S.; Zhuo, L.-S.; Yang, F.-P.; Wang, W.-J.; Huang, W.; Yang, G.-F. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold. Eur. J. Med. Chem. 2019, 185, 111803. [Google Scholar] [CrossRef] [PubMed]
  23. Wu, F.; Zhuo, L.; Wang, F.; Huang, W.; Hao, G.; Yang, G.-F. Auto in Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead. iScience 2020, 23, 101179. [Google Scholar] [CrossRef]
  24. Gopalsamy, A.; Shi, M.; Boschelli, D.H.; Williamson, R.; Olland, A.; Hu, Y.; Krishnamurthy, G.; Han, X.; Arndt, A.K.; Guo, B. Discovery of Dibenzo[c,f][2,7]naphthyridines as Potent and Selective 3-Phosphoinositide-Dependent Kinase-1 Inhibitors. J. Med. Chem. 2007, 50, 5547–5549. [Google Scholar] [CrossRef] [PubMed]
  25. Litvinov, V. Advances in the Chemistry of Naphthyridines. Adv. Heterocycl. Chem. 2006, 91, 189–300. [Google Scholar] [CrossRef]
  26. Suzuki, H.; Sakai, N.; Iwahara, R.; Fujiwaka, T.; Satoh, M.; Kakehi, A.; Konakahara, T. Novel Synthesis of 7-Fluoro-8-(trifluoromethyl)- 1H-1,6-naphthyridin-4-one Derivatives: Intermolecular Cyclization of anN-Silyl-1-azaallyl Anion with Perfluoroalkene and Subsequent Intramolecular Skeletal Transformation of the Resulting Pentasubstituted Pyridines. J. Org. Chem. 2007, 72, 5878–5881. [Google Scholar] [CrossRef]
  27. Morgentin, R.; Pasquet, G.; Boutron, P.; Jung, F.; Lamorlette, M.; Maudet, M.; Ple, P. Strategic studies in the syntheses of novel 6,7-substituted quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones. Tetrahedron 2008, 64, 2772–2782. [Google Scholar] [CrossRef]
  28. Zeng, L.-F.; Wang, Y.; Kazemi, R.; Xu, S.; Xu, Z.-L.; Sanchez, T.W.; Yang, L.-M.; Debnath, B.; Odde, S.; Xie, H.; et al. Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties. J. Med. Chem. 2012, 55, 9492–9509. [Google Scholar] [CrossRef]
  29. Falardeau, G.; Lachance, H.; St-Pierre, A.; Yannopoulos, C.G.; Drouin, M.; Bédard, J.; Chan, L. Design and synthesis of a potent macrocyclic 1,6-napthyridine anti-human cytomegalovirus (HCMV) inhibitors. Bioorganic Med. Chem. Lett. 2005, 15, 1693–1695. [Google Scholar] [CrossRef]
  30. Wang, Y.; Bullock, W.H.; Chen, L. 1,6-naphthyridine Derivatives as Antidiabetics. WO 03027113A1, 3 April 2003. [Google Scholar]
  31. Sanchez, J.P.; Gogliotti, R.D. The synthesis of a series of 7-amino-1-cyclopropyl-8-fluoro-1,4-dihydro-4-oxo-1,6-naphthyridine-3-carboxylic acids as potential antibacterial agents. J. Heterocycl. Chem. 1993, 30, 855–859. [Google Scholar] [CrossRef]
  32. Gündisch, D.; Eibl, C. Nicotinic acetylcholine receptor ligands, a patent review (2006–2011). Expert Opin. Ther. Patents 2011, 21, 1867–1896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Richard, K. Alpha7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof. WO 2010083444A1, 15 January 2009. [Google Scholar]
  34. Dembélé, O.; Montoir, D.; Yvorra, T.; Sérillon, D.; Tonnerre, A.; Duflos, M.; Robert, J.-M.; Bazin, M.-A. Novel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and SNAr reactions of a dihalogenated compound. Tetrahedron Lett. 2018, 59, 3519–3523. [Google Scholar] [CrossRef]
  35. Kumpiņa, I.; Isaksson, R.; Sävmarker, J.; Wannberg, J.; Larhed, M. Microwave Promoted Transcarbamylation Reaction of Sulfonylcarbamates under Continuous-Flow Conditions. Org. Process. Res. Dev. 2016, 20, 440–445. [Google Scholar] [CrossRef]
  36. Tabarrini, O.; Stevens, M.; Cecchetti, V.; Sabatini, S.; Dell’Uomo, M.; Manfroni, G.; Palumbo, M.; Pannecouque, C.; De Clercq, E.; Fravolini, A. Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. J. Med. Chem. 2004, 47, 5567–5578. [Google Scholar] [CrossRef] [PubMed]
Molecules 25 05667 g001 550
Figure 1. Representative 1,6-naphthyride- or 1,6-naphthyridin-4-one-based pharmacologically active compounds.
Figure 1. Representative 1,6-naphthyride- or 1,6-naphthyridin-4-one-based pharmacologically active compounds.
Molecules 25 05667 g001
Molecules 25 05667 g002 550
Figure 2. Discovery of bioactive 5-amino-3-phenyl-1,6-naphthyridin-4-one derivatives VI, VII and proposed future work.
Figure 2. Discovery of bioactive 5-amino-3-phenyl-1,6-naphthyridin-4-one derivatives VI, VII and proposed future work.
Molecules 25 05667 g002
Molecules 25 05667 sch001 550
Scheme 1. Common construction strategies of the 3-phenyl-1,6-naphthyridin-4-one scaffold: (a) Suzuki–Miyaura coupling-based construction of 7-functionalized 1,6-naphthyridin-4-one 7; (b) Conrad–Limpach cyclizations-based construction of 5-chloro-3- substituted-1,6-naphthyridin-4-one derivatives 13a; (c) Grignard reagent-based strategy for the construction of diversified 5-chloro-3- substituted-1,6-naphthyridin-4-one derivatives 13.
Scheme 1. Common construction strategies of the 3-phenyl-1,6-naphthyridin-4-one scaffold: (a) Suzuki–Miyaura coupling-based construction of 7-functionalized 1,6-naphthyridin-4-one 7; (b) Conrad–Limpach cyclizations-based construction of 5-chloro-3- substituted-1,6-naphthyridin-4-one derivatives 13a; (c) Grignard reagent-based strategy for the construction of diversified 5-chloro-3- substituted-1,6-naphthyridin-4-one derivatives 13.
Molecules 25 05667 sch001
Molecules 25 05667 sch002 550
Scheme 2. Retrosynthetic analysis of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one.
Scheme 2. Retrosynthetic analysis of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one.
Molecules 25 05667 sch002
Molecules 25 05667 sch003 550
Scheme 3. An overall synthetic route of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one.
Scheme 3. An overall synthetic route of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one.
Molecules 25 05667 sch003
Molecules 25 05667 sch004 550
Scheme 4. Our planned route to key intermediate 17a.
Scheme 4. Our planned route to key intermediate 17a.
Molecules 25 05667 sch004
Molecules 25 05667 sch005 550
Scheme 5. Grignard reagent scope for the construction of 1, 6-naphthyridin-4-one scaffold. (a) 1.5 mmol of 4-amino-2-chloronicotinonitrile (15) and 6.0 mmol of Grignard reagent (16) in 3.0 mL of ether at 30 °C for 12 h under an N2 atmosphere; (b) 6 mL of the HCl/H2O/EtOH (1:1:2) solvent was added for acidolysis; (c) Isolated yield.
Scheme 5. Grignard reagent scope for the construction of 1, 6-naphthyridin-4-one scaffold. (a) 1.5 mmol of 4-amino-2-chloronicotinonitrile (15) and 6.0 mmol of Grignard reagent (16) in 3.0 mL of ether at 30 °C for 12 h under an N2 atmosphere; (b) 6 mL of the HCl/H2O/EtOH (1:1:2) solvent was added for acidolysis; (c) Isolated yield.
Molecules 25 05667 sch005
Molecules 25 05667 sch006 550
Scheme 6. Our planned route to target molecule 13a.
Scheme 6. Our planned route to target molecule 13a.
Molecules 25 05667 sch006
Molecules 25 05667 sch007 550
Scheme 7. Synthesis of 1,6-naphthyridin-4-one derivatives. (a) 0.5 mmol of 1-(4-amino-2-chloropyridin-3-yl)-2-substituted-ethan-1-one (17) and 0.05 mmol of DMAP in 1.0 mL triethyl orthoformate (13a–n) or triethyl orthoacetate (13o) at 110 °C for 24 h; (b) Isolated yield.
Scheme 7. Synthesis of 1,6-naphthyridin-4-one derivatives. (a) 0.5 mmol of 1-(4-amino-2-chloropyridin-3-yl)-2-substituted-ethan-1-one (17) and 0.05 mmol of DMAP in 1.0 mL triethyl orthoformate (13a–n) or triethyl orthoacetate (13o) at 110 °C for 24 h; (b) Isolated yield.
Molecules 25 05667 sch007
Molecules 25 05667 sch008 550
Scheme 8. The 100 g scale synthesis of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one and its application in preclinical drug candidate enrichment.
Scheme 8. The 100 g scale synthesis of 5-chloro-3-(4-fluorophenyl)-1,6-naphthyridin-4-one and its application in preclinical drug candidate enrichment.
Molecules 25 05667 sch008
Table
Table 1. Optimization of the reaction conditions a,b for the synthesis of 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a).
Table 1. Optimization of the reaction conditions a,b for the synthesis of 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (17a).
Entry2–5 Equiv.SolventTemp. (°C)Reaction Time (h)Yield c (%)
12THF25165
22Et2O251620
32Et2O301235
42Methyl tert-butyl ether301210
52Isopropyl ether30127
62Toluene3012Trace
73Et2O301260
84Et2O301274
95Et2O301273
a Reactions were performed using 0.5 mmol of 4-amino-2-chloronicotinonitrile (15) in 1.0 mL solvent under N2 atmosphere. b 2 mL HCl/H2O/EtOH (1:1:2) solvent was added for acidolysis. c Isolated yield.
Table
Table 2. Optimization of the reaction conditions a for the cyclocondensation.
Table 2. Optimization of the reaction conditions a for the cyclocondensation.
EntryBase (equiv.)SolventTemp. (°C)Reaction Time (h)Yield b (%)
1K2CO3 (2eq)DMF11024<1
2NaH (2eq)THF6024<1
3Et3N (2eq)DMF1102415
4DIPEA (2eq)DMF1102430
5DMAP (2eq)DMF1102465
6DMAP (2eq)HC(OEt)31102470
7DMAP (1eq)HC(OEt)31102470
8DMAP (0.1 eq)HC(OEt)31102472
9No catalystHC(OEt)3110240
a Reactions were performed using 0.5 mmol of 1-(4-amino-2-chloropyridin-3-yl)-2-(4-fluorophenyl)ethan-1-one (13a) in 1.0 mL of solvent under an air atmosphere. b Isolated yields.
Sample Availability: Not available.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Wang, M.-S.; Gong, Y.; Yu, Z.-C.; Tian, Y.-G.; Zhuo, L.-S.; Huang, W.; She, N.-F. Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives. Molecules 2020, 25, 5667. https://doi.org/10.3390/molecules25235667

AMA Style

Wang M-S, Gong Y, Yu Z-C, Tian Y-G, Zhuo L-S, Huang W, She N-F. Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives. Molecules. 2020; 25(23):5667. https://doi.org/10.3390/molecules25235667

Chicago/Turabian Style

Wang, Ming-Shu, Yi Gong, Zhi-Cheng Yu, Yan-Guang Tian, Lin-Sheng Zhuo, Wei Huang, and Neng-Fang She. 2020. "Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives" Molecules 25, no. 23: 5667. https://doi.org/10.3390/molecules25235667

Article Metrics

Back to TopTop